{"commentary":{"count":18,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":10,"podcast":4,"x_thread":3,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07276399\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"OrigAMI-5","nct_id":"NCT07276399","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=origami-5-nct07276399. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"OrigAMI-5","arms":[{"description":"Participants will receive pembrolizumab, amivantamab and carboplatin.","label":"Arm A: Pembrolizumab, Amivantamab, Carboplatin","type":"EXPERIMENTAL"},{"description":"Participants will receive pembrolizumab, 5-FU and carboplatin or cisplatin (platinum therapy).","label":"Arm B: Pembrolizumab, 5-Flurouracil (5-FU), Carboplatin or Cisplatin","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-06-18","type":"ESTIMATED"},"conditions":["Squamous Cell Carcinoma of Head and Neck"],"enrollment":{"count":500,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Amivantamab","type":"BIOLOGICAL"},{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Carboplatin","type":"DRUG"},{"name":"5-Flurouracil","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-06-18","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 3 years 7 months"},{"measure":"Objective Response Rate (ORR) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 3 years 7 months"}],"references":[],"start_date":{"date":"2025-12-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","url":"https://clinicaltrials.gov/study/NCT07276399"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/origami-5-nct07276399"}